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Previous observational studies on statins have shown variable results based on the methodology used. Our ob-
jective was to study the association between statins and orthopedic implant failure and to explore the influence of
methodological differences in study design. Our study base consisted of patients with a primary total joint replace-
ment in Denmark and the United Kingdom (n = 189,286; 1987–2012). We used 4 study designs: 1) case-control
(each patient with revision surgery matched to 4 controls), 2) time-dependent cohort (postoperative statin use as
a time-varying exposure variable), 3) immortal time cohort (misclassifying the time postoperatively before statin
use), and 4) time-exclusion cohort (excluding the time postoperatively before statin use). Cox proportional hazards
models and logistic regression were used to estimate incidence rate ratios. In the time-dependent cohort design,
statin use was associated with a decreased risk of revision surgery (adjusted incidence rate ratio (IRR) = 0.90, 95%
confidence interval (CI): 0.85, 0.96), which was similar to our case-control results (IRR = 0.87, 95% CI: 0.81, 0.93).
In contrast, both time-fixed cohort designs yielded substantially lower risk estimates (IRR = 0.36 (95% CI: 0.34,
0.38) and IRR = 0.65 (95% CI: 0.63, 0.68), respectively). We discourage the use of time-fixed cohort studies,
which may falsely suggest protective effects. The simple choice of how to classify exposure can substantially
change results from biologically plausible to implausible.
arthroplasty; case-control studies; cohort studies; hydroxymethylglutaryl-CoA reductase inhibitors;
pharmacoepidemiology
Abbreviations: CI, confidence interval; CPRD, Clinical Practice Research Datalink; DNHS, Danish National Health System; GPRD,
General Practice Research Database; IRR, incidence rate ratio; TJR, total joint replacement.
Primary total joint replacements (TJRs) of the hip and knee
substantially alleviate pain and improve physical function
and quality of life in patients with moderate to severe osteo-
arthritis (1). Each year, approximately 1.8 million of these
procedures are performed worldwide (2, 3). Up to 8.3% of
recipients need their joint implants revised in the first 10
years (4), and these revisions are associated with poorer clin-
ical outcomes compared with primary TJR (5, 6).
Observational studies have suggested many beneficial
pleiotropic effects of statins, including a reduced risk of frac-
ture and cancer (7, 8). Similarly, statins have been proposed
to prevent implant revision failure (9). In a Danish case-
control study, Thillemann et al. (9) reported a 66% reduction
in implant revision with statin use, although they could not
find a dose-response relationship.
These potential beneficial effects could be explained on a bi-
ological etiological basis (10–12). However, the seemingly
beneficial effects from observational studies could also be ex-
plained by study design and analytical choices. Previous stud-
ies on statins have shown discrepant results when the datawere
analyzed for a second time in the exact same database. For ex-
ample, in the first British observational study, Meier et al. (7)
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used the General Practice Research Database (GPRD) to exam-
ine the risk of fracture with statin use and reported an odds ratio
of 0.55 (95% confidence interval (CI): 0.44, 0.69). In contrast,
in the second study using theGPRD, van Staa et al. (13) did not
find such a protective effect. In a third GPRD study, examining
the reasons for the discrepant results, de Vries et al. (14) found
that the age band for matching cases and controls, the selection
of potential confounders, the exclusion of high-risk patients,
and different definitions for exposure time windows could ex-
plain the different results between the first 2 GPRD studies.
Similarly, a British cohort study on bisphosphonates showed
a 46% reduction in joint implant failure (15), whereas a 34%
detrimental trendwas found in aDanish case-control study (16).
These reanalyses have taught us that arbitrary decisions in
observational studies may have a large impact on the study
results and need to be explored in great detail. Some of the
microdecisions that have been hypothesized to influence
study results include: 1) use of case-control designs versus
cohort designs, 2) use of time-dependent cohort designs ver-
sus time-fixed cohort designs, 3) selection of confounders,
4) techniques for dealing with confounding (including pro-
pensity score analyses), and 5) selection of the data source
(e.g., hospitalization registries or general practice–based
electronic health records) (14, 17, 18). As Suissa et al. (17)
demonstrated, we can expect a large impact from the expo-
sure classification (i.e., time-dependent vs. time-fixed cohort
designs). Given the increase in popularity of the time-fixed
cohort design—in particular when evaluating the protective
effect of medications on implant failure (15)—we sought to
further build on these findings in the present study. In con-
trast, we expected no substantial difference between the var-
ious methods to deal with confounding using electronic
health records (despite major efforts to optimize these tech-
niques). The confounding data in electronic health records
are often limited by the quality of the data itself, but this
has not been studied comprehensively before.
The objectives of this study were 1) to evaluate the associ-
ation between statins and implant failure in patients with pri-
mary TJR surgery, 2) to study the impact of differences in
study design, and 3) to assess the influence of using 2 differ-
ent data sources.
METHODS
Source population
We conducted a retrospective multicountry study using
data from the Clinical Practice Research Datalink (CPRD),
previously known as the GPRD, and the Danish National
Health System (DNHS). The CPRD collates the computer-
ized medical records of general practitioners. The data
recorded in the CPRD since 1987 include demographic
information, prescription details, clinical events, preventive
care provided, specialist referrals, hospital admissions, and
major outcomes (https://www.CPRD.com). The DNHS
keeps computerized medical records on all contacts with hos-
pitals and general practitioners and on income, degree of
education, working status, civil status, migrations, the use
of medications, and causes of death for the entire Danish
population (5.5 million inhabitants). In both data sources,
data recording occurred in a prospective manner (i.e., it is
not likely that exposure misclassification rates might be
differential by outcome status).
Study base
The study base consisted of all patients with a primary TJR
during the study period (CPRD: January 1, 1987 to August 31,
2012; DNHS: January 1, 1998 toDecember 31, 2007, the latest
available data). We restricted TJR surgeries to procedures that
were likely to be elective. All subjects were at least 40 years of
age, had no record of hip or knee fracture in the previous 3
months, and had no history of rheumatoid arthritis. Patients
were followed from the date of the primary TJR surgery to
the end of data collection, the date of transfer of the patient
out of the practice area (CPRD)/migration, the patient’s
death, or a revision TJR, whichever came first.
Outcome of interest
The outcome of interest concerned implant revision sur-
gery. In CPRD data, we identified revision surgery using
CPRD Read codes. International Classification Diseases,
Tenth Edition, procedure codes NFC and NGC were used
to detect revision surgery in DNHS data.
Cohort design
Time-dependent cohort study. In this study design, statin
exposure was defined in a time-dependent manner (see Fig-
ure 1). For statin users, total follow-up time was divided into
2 periods: 1) the first period started at the time of the primary
TJR surgery and ended 1 day before the first postoperative
statin prescription (this period was defined as nonuse), and
2) the second period started at the date of first postoperative
statin prescription and ended at the end of follow-up. Individ-
uals whowere exposed to statins only before the primary TJR
surgery were classified as nonusers. For statin nonusers, the
total follow-up period was considered a period of nonuse.
Time-fixed immortal time cohort. For this design, the pa-
tient was defined as either a statin nonuser or a statin user
and, consequently, could not move between these exposure sta-
tuses. Statin users were those with at least 1 statin prescription
between the primary TJR surgery and the end of follow-up. All
other patients were considered nonusers. Start of follow-up
was defined as the date of the primary TJR surgery, regardless
of exposure status.
Time-fixed exclusion cohort. This cohort design was sim-
ilar to the time-fixed immortal time cohort design, with the ex-
ception of the start of follow-up. For statin users, the start of
follow-up was defined as the date of the first postoperative sta-
tin prescription (i.e., the immortal time was excluded). For
nonusers, the date of the primary TJR surgery remained the
start of follow-up.
Case-control design. Nestedwithin our study base, we se-
lected all participants who underwent revision surgery, the
date of which was considered the index date. For each case,
up to 4 control individuals without revision surgery were se-
lected using incidence density sampling. The index dates for
the controls were imputed from the corresponding case. Statin
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exposurewas defined as having at least 1 statin prescription be-
tween the date of the primary TJR and the index date.
Potential confounders
The presence of risk factors was assessed at baseline—that
is, on the date of the primary TJR surgery. Risk factors for
implant failure were selected on the basis of their association
with bone remodeling. These included age, sex, type of joint
replaced (hip or knee), year of the primary TJR, and prior
fractures. Further, we evaluated a history of comorbid dis-
eases (osteoarthritis, inflammatory bowel disease, any ma-
lignancy, congestive heart failure, ischemic heart disease,
cerebrovascular disease, rheumatoid arthritis, and chronic
obstructive pulmonary disease) and use in the previous
6 months of medications that might affect bone modeling
(bisphosphonates, calcium or vitamin D supplements, hor-
mone replacement therapy, selective estrogen receptor mod-
ulators, glucose-lowering agents, proton pump inhibitors,
antiarrhythmics, anticonvulsants, antidepressants, antipar-
kinsonian drugs, thiazide diuretics, and anxiolytics). For
the CPRD population, we made additional adjustments for
body mass index, smoking status, and alcohol use. All covari-
ates (except age and body mass index) were treated as categor-
ical variables, andmissing informationwas treated as a separate
category. Age and body mass index were handled as continu-
ous variables (single linear terms).
As an additional step in the cohort studies, we further adjusted
the analyses in a time-dependent manner. Total follow-up was
divided into 90-day periods (Figure 1), and the confounder sta-
tus was assessed at the start of each time interval.
Statistical analysis
For the cohort designs, incidence rate ratios were estimated
using Cox proportional hazards models (PHREG procedure;
SAS, version 9.2, SAS Institute, Inc., Cary, North Carolina),
comparing revision rates in statin users with those in nonus-
ers. For the case-control design, we used logistic regression
(LOGISTIC procedure; SAS, version 9.2). Conditional logis-
tic regression was used for the propensity-matched case-
control design. The hazard ratios from the cohort studies
and the odds ratios from the case-control study are both esti-
mates of the incidence rate ratio; hence, we expressed the risk
estimates for all analyses as incidence rate ratios. We de-
termined the influence of different confounder adjustment
models:
1. No adjustments (crude)
2. Adjusted for age and sex
3. Additionally adjusted for comorbid diseases and drug use
4. Additionally adjusted for lifestyle parameters
5. Additionally adjusted for calendar time
6. Additionally adjusted for all potential confounders in a
time-dependent fashion (this was considered the fully ad-
justed model)
7. Adjusted for all covariates that change the β coefficient for
statin use by at least 1%, 5%, and 10% (change-in-estimate
method). The change-in-estimate procedure was carried
out evaluating each covariate on its own (comparing
crude estimates with univariately adjusted estimates).
8. Propensity-adjusted model (including all potential con-
founders in the propensity model)
9. Propensity-matched model: In the cohort design, current
statin users were matched to 1 nonuser by propensity
score, modeled for statin use, with a maximum caliper
width of 0.02 standard deviation; all potential confound-
ers (assessed at the time of the primary TJR surgery) were
included in the propensity model. In the case-control de-
sign, up to 4 controls were matched to each case using the
same propensity score technique. Using this technique, we
maintained incidence density sampling and were able to
identify exactly 4 controls for each identified case.
Primary TJR
Surgery
Revision
Surgery
First Postoperative
Statin Prescription
Nonuse Statin Use
90d   90d   90d   90d         90d   90d   90d   90d   90d   90d   90d   90d     
Misclassified Time
Excluded Time
Time-Dependent:
Time-Fixed, Method 2:
Time-Fixed, Method 1: Statin Use
Statin Use
Figure 1. Overview of the 3 different cohort approaches used in this analysis of statin use and risk of implant revision surgery in the United King-
dom and Denmark, 1987–2012. Top row: time-dependent exposure status in which each patient may contribute to both “statin nonuse” and “statin
use” groups. Middle row: time-fixed approach (method 1), (incorrectly) allocating immortal time before the first statin prescription to the statin use
group (misclassification bias). Bottom row: time-fixed approach (method 2), excluding immortal time before the first statin prescription (selection
bias). Medium gray shading represents statin use, light gray shading represents nonuse, and boxes with dashed borders represent excluded
person-time. d, days; TJR, total joint replacement.
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Table 1. Baseline Characteristics of Statin Users and Nonusers, United Kingdom and Denmark, 1987–2012
Characteristic
United Kingdom (CPRD) Denmark (DNHS)
Statin Use
(n = 49,265), Mean (SD)
Nonuse
(n = 69,917), Mean (SD)
Statin Use
(n = 17,168), Mean (SD)
Nonuse
(n = 52,936), Mean (SD)
% % % %
Follow-up, years 6.1 (4.1) 5.2 (4.0) 4.4 (2.7) 3.9 (2.7)
Age at index date, years 70.2 (8.5) 69.5 (10.9) 68.2 (8.5) 68.3 (10.6)
Female sex 53.8 63.4 55.8 59.4
Body mass indexa,b 29.2 (5.1) 27.9 (5.3)
Smoking statusc
Never smoker 54.3 61.7
Current smoker 11.9 11.7
Former smoker 33.7 24.2
Alcohol used
No 21.4 19.2
Yes 74.9 70.3
Medication use within
6 months before index date
Calcium or vitamin D 6.4 6.6 1.2 1.3
Oral corticosteroids 4.9 5.0 8.4 8.1
Noninsulin antidiabetics 12.0 2.1 14.1 2.9
Thiazide diuretics 28.3 18.8 22.9 17.5
Paracetamol or
acetaminophen
62.5 56.4 33.8 30.4
NSAIDs 52.0 52.6 62.0 61.6
Opioids (tramadol or stronger) 37.1 34.8 29.4 28.4
Bisphosphonates 4.7 4.7 2.3 2.7
β blockers 25.4 10.7 23.8 11.1
Antiplatelet drugs 37.7 11.2 35.4 13.3
Anxiolytics or hypnotics 10.2 10.1 24.3 22.6
Proton pump inhibitors 27.5 20.8 13.6 10.4
Disease history before index
date
Fracture 20.7 20.5 21.6 24.0
Osteoarthritis 76.4 72.0 97.8 97.4
Rheumatoid arthritis 4.0 5.1 3.0 4.0
Chronic kidney disease 8.9 4.5 1.0 0.7
Heart failure 4.1 2.7 7.2 4.0
Ischemic heart disease 24.9 5.7 23.8 6.3
Cerebrovascular disease 9.9 3.6 7.2 2.9
Hyperlipidemia 24.0 4.5 11.6 0.8
Atrial fibrillation 5.1 3.3 6.6 4.2
Hypertension 57.7 34.6 21.6 9.8
Type 2 diabetes mellitus 15.5 2.5 10.6 2.2
COPD 4.6 3.8 4.9 4.4
Asthma 12.4 11.4 2.6 2.4
Abbreviations: COPD, chronic obstructive pulmonary disease; CPRD, Clinical Practice Research Datalink; DNHS, Danish National Health
System; NSAID, nonsteroidal antiinflammatory drug; SD, standard deviation.
a Missing proportions in the CPRD: statin users, 2.7%; nonusers, 10.5%.
b Calculated as weight (kg)/height (m)2.
c Missing proportions in the CPRD: statin users, 0.1%; nonusers, 2.4%.
d Missing proportions in the CPRD: statin users, 3.6%; nonusers, 10.5%.
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To illustrate the dose-time-response relationship, we used
smoothing spline regression to visualize the incidence rate
ratio for revision surgery in relation to the cumulative number
of statin daily defined doses after the primary TJR surgery
(19–21).
Multicountry analysis. In order to evaluate regional differ-
ences, we conducted all of the above-mentioned analyses
using the CPRD and DNHS databases separately, and accord-
ingly, compared them against each other. Further, to aggregate
the British and Danish results, we performed both an individ-
ual patient–level meta-analysis (lumping all individuals into a
“mega-analysis”) and a classical meta-analysis (i.e., combin-
ing the incidence rate ratio estimates from the 2 separate data
sources). When adjusting for potential confounders in the ag-
gregation analysis, we considered only confounder data that
were available in both databases. In the mega-analysis, we
tested for multiplicative interaction (cross-product terms for
statin use and database) as well as additive interaction between
the 2 databases. For the classical meta-analysis, we used an
inverse-variance fixed-effect design (Review Manager (Rev-
Man), version 5.2; Nordic Cochrane Center (Cochrane Collab-
oration), Copenhagen, Denmark).
RESULTS
We identified 119,182 British patients and 70,104Danish pa-
tients who underwent primary TJR surgery (Table 1). Among
these patients, 41.3% (n = 49,265) were classified as postopera-
tive statin users in the British cohort, and 24.5% (n = 17,168)
were classified as postoperative statin users in theDanish cohort.
Baseline characteristics were very similar in the 2 data sources.
Overall, statin users and nonusers had a similar mean age (ap-
proximately 70 years in British participants and approximately
68 years in Danish participants), and a higher proportion of sta-
tin users were males. We had a longer follow-up period in the
British cohort (6.1 years for statin users and 5.2 years for non-
users) than in the Danish cohort (4.4 years for statin users and
3.9 years for nonusers). In both cohorts, statin users were more
likely to have used glucose-lowering drugs and thiazide di-
uretics andmore often had a history of ischemic heart disease,
cerebrovascular disease, or hyperlipidemia. Among persons
included in the cohorts, 3,517 British participants and 3,747
Danish participants underwent revision surgery. They were
Table 2. Risk of Orthopedic Implant Revision Surgery According to Statin Use, by Study Design, United Kingdom and Denmark, 1987–2012
Cohort Design
No Statin Use Statin Use
IRR
No. of
Events
No. of
Person-Years
Rate per 10,000
Person-Years
Events,
%a
IRRb 95% CI
No. of
Events
No. of
Person-Years
Rate per 10,000
Person-Years
Events,
%a
United Kingdom (CPRD)
Time-fixed (misclassification) 1 2,471 359,856 68.7 3.5 0.36 0.33, 0.39 1,046 299,640 34.9 2.1
Time-fixed (exclusion) 1 2,471 359,856 68.7 3.5 0.64 0.58, 0.71 1,046 210,395 49.7 2.1
Time-dependent 1 2,471 449,101 55.0 3.5 0.92 0.84, 1.01 1,046 210,395 49.7 2.1
Case-control 1 2,471 0.87 0.79, 0.95 1,046
Denmark (DNHS)
Time-fixed (misclassification) 1 3,220 207,154 155.4 6.1 0.36 0.33, 0.40 527 74,655 70.6 3.1
Time-fixed (exclusion) 1 3,220 207,154 155.4 6.1 0.65 0.59, 0.72 527 42,510 124.0 3.1
Time-dependent 1 3,220 239,298 134.6 6.1 0.90 0.81, 0.99 527 42,510 124.0 3.1
Case-control 1 3,220 0.85 0.76, 0.95 527
Abbreviations: CI, confidence interval; CPRD, Clinical Practice Research Datalink; DNHS, Danish National Health System; IRR, incidence rate ratio.
a Percentage of patients at risk who had events.
b Adjusted for age, sex, type of replaced joint, year of the primary surgery, history of fracture, comorbid diseases (osteoarthritis, inflammatory bowel disease, any
malignancy, congestive heart failure, ischemic heart disease, cerebrovascular disease, rheumatoid arthritis, and chronic obstructive pulmonary disease), and
medication use (bisphosphonates, calcium or vitamin D supplements, hormone replacement therapy, selective estrogen receptor modulators, glucose-lowering
agents, proton pump inhibitors, antiarrhythmics, anticonvulsants, antidepressants, antiparkinsonian drugs, thiazide diuretics, and anxiolytics). With CPRD data,
results were additionally adjusted for body mass index, smoking status, and alcohol use.
10.0
1.0
0.1
A
dj
us
te
d 
IR
R
0 1 2 3 4 5 6 7
Cumulative Statin DDD Exposure (× 365)
Time-Dependent
Time-Fixed 1
Time-Fixed 2
Case-Control
Figure 2. Spline regression plot of statin use and risk of implant re-
vision surgery in relation to cumulative statin exposure (daily defined
dose (DDD)), according to study design, United Kingdom, 1987–2012.
Data from the Clinical Practice Research Datalink were used for this
analysis. Yearly use was divided by the quantity corresponding to 1
DDD. The total number of DDDs used for statins during the study pe-
riod was obtained as the sum of yearly DDDs. Results shown are from
fully adjusted models. Time-fixed method 1 included misclassification
of immortal time; time-fixed method 2 included exclusion of immortal
time. IRR, incidence rate ratio.
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included in the case-control design and matched to 14,068 Brit-
ish and 14,988 Danish control subjects who did not undergo re-
vision surgery.
Table 2 shows that there were no substantial differences
between the results of the time-dependent cohort studyand the
case-control study. In British participants, the time-dependent
cohort study yielded an adjusted incidence rate ratio of 0.92
(95% CI: 0.84, 1.01), closely resembling the risk estimate
for the case-control study (adjusted incidence rate ratio (IRR) =
0.87, 95% CI: 0.79, 0.95). In contrast, both time-fixed co-
hort studies yielded substantially different results compared
with the time-dependent cohort study and the case-control
study (Table 2). Also in the British population, misclassifi-
cation of immortal time resulted in an adjusted incidence
rate ratio of 0.36 (95% CI: 0.33, 0.39). The association
weakened, but risk remained substantially lower, when the
period of time prior to starting a statin was excluded (adjusted
IRR = 0.64, 95% CI: 0.58, 0.71). Both time-fixed approaches
showed a significant relationship between the cumulative du-
ration of statin use and the risk of revision surgery (Figure 2).
This sharply contrasted with the time-dependent cohort study
and the case-control study, which did not show such rela-
tionships. The same findings were observed in the Danish
population.
Table 3. Riskof Orthopedic Implant Revision Surgery AmongStatin Usersa According toMethodUsed to DealWith Confounding, Clinical Practice
Research Datalink, United Kingdom, 1987–2012
Confounder-Handling
Technique
Cohort Design
Case-Control DesignTime-Fixed
Time-Dependent
Method 1b Method 2c
IRR 95% CI IRR 95% CI IRR 95% CI IRR 95% CI
Unadjustedd 0.51 0.47, 0.55 0.72 0.67, 0.78 0.90 0.84, 0.97 0.89 0.82, 0.95
Cox proportional hazards regression
Adjustments (at baseline only)
Age and sex 0.50 0.46, 0.54 0.73 0.67, 0.78 0.93 0.86, 1.00 0.89 0.83, 0.96
Plus comorbid diseases or drug usee 0.42 0.39, 0.46 0.67 0.61, 0.73 0.90 0.83, 0.98 0.88 0.81, 0.97
Plus lifestyle factorsf 0.42 0.38, 0.45 0.65 0.60, 0.71 0.90 0.82, 0.97 0.88 0.80, 0.96
Plus calendar time 0.42 0.38, 0.45 0.66 0.61, 0.72 0.91 0.84, 0.99 0.87 0.79, 0.95
Plus time-dependent adjustment 0.36 0.33, 0.39 0.64 0.58, 0.71 0.92 0.84, 1.01
Change-in-estimate method
>1% changeg 0.43 0.40, 0.47 0.67 0.62, 0.73 0.92 0.84, 1.01 0.86 0.79, 0.95
>5% changeh 0.45 0.41, 0.48 0.67 0.62, 0.73 0.92 0.84, 1.01 0.86 0.78, 0.95
>10% changei 0.51 0.47, 0.55 0.72 0.67, 0.78 0.96 0.88, 1.04 0.89 0.83, 0.96
Propensity scorej 0.44 0.40, 0.47 0.67 0.61, 0.73 0.96 0.88, 1.04 0.85 0.78, 0.94
Propensity-matchedj 0.41 0.37, 0.45 0.65 0.59, 0.71 0.96 0.87, 1.05 0.85 0.77, 0.95
Abbreviations: CI, confidence interval; IRR, incidence rate ratio.
a Referent: no statin use (IRR = 1).
b Misclassification of immortal time.
c Exclusion of immortal time.
d Not adjusted for any of the potential confounders, including age and sex.
e Adjusted for age, sex, type of replaced joint, year of the primary surgery, history of fracture, comorbid diseases (osteoarthritis, inflammatory bowel
disease, any malignancy, congestive heart failure, ischemic heart disease, cerebrovascular disease, rheumatoid arthritis, and chronic obstructive
pulmonary disease), and drug use (bisphosphonates, calcium or vitamin D supplements, hormone replacement therapy, selective estrogen receptor
modulators, glucose-lowering agents, proton pump inhibitors, antiarrhythmics, anticonvulsants, antidepressants, antiparkinsonian drugs, thiazide
diuretics, and anxiolytics).
f Adjusted for variables listed in footnote e and for lifestyle factors (body mass index, smoking status, alcohol use, and general practitioner
deprivation score (25)).
g Cohort design: adjusted for age, sex, type of replaced joint, year of the primary surgery, use of thiazide diuretics, a history of cerebrovascular
disease, body mass index, and smoking status. Case-control design: adjusted for age, sex, use of proton pump inhibitors, a history of
cerebrovascular disease, body mass index, and smoking.
h Cohort design: adjusted for variables listed in footnote g and for the use of glucose-lowering drugs, proton pump inhibitors, and antidepressants.
Case-control design: adjusted for variables listed in footnote g and for alcohol use, congestive heart failure, ischemic heart disease, and the use of
glucose-lowering drugs, anticonvulsants, and antidepressants.
i Cohort design: adjusted for variables listed in footnote g and for hormone replacement therapy, antiparkinsonian drugs, congestive heart failure,
ischemic heart disease, and chronic obstructive pulmonary disease. Case-control design: adjusted for variables listed in footnote g and for alcohol use,
use of glucose-lowering drugs, antiarrhythmics, thiazide diuretics, and anxiolytics, history of fracture, and chronic obstructive pulmonary disease.
j Propensity model (outcome = statin use) included all potential confounders and yielded a C statistic score of 0.80 for all 3 cohort designs and
0.89 for the case-control design.
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There were no substantial differences between the various
techniques for dealing with confounding (Table 3). For exam-
ple, in the British cohort, using a time-dependent approach, the
fully adjusted incidence rate ratio was 0.92 (95% CI: 0.84,
1.01). The incidence rate ratio was 0.92 (95% CI: 0.84, 1.01)
with the change-in-estimate method (1% change), 0.96 (95%
CI: 0.88, 1.04) using propensity-adjusted models, and 0.96
(95% CI: 0.87, 1.05) with the propensity-matched models.
The same trend was present in the Danish analyses (data not
shown).
In a sensitivity analysis, we imputed the missing data, but
this did not substantially alter our findings. For example, in
the CPRD data set, modeling the missing data category
yielded an adjusted incidence rate ratio of 0.92 (95% CI:
0.84, 1.01) as compared with an adjusted incidence rate
ratio of 0.94 (95% CI: 0.85, 1.04) when missing data were
imputed. Both estimates were obtained using the fully ad-
justed time-dependent model.
Table 4 shows the results of aggregating the British and
Danish findings. Using the time-dependent approach, the in-
dividual patient–level mega-analysis yielded an adjusted in-
cidence rate ratio of 0.90 (95% CI: 0.85, 0.96), which was
comparable to the result of the classical meta-analysis (ad-
justed IRR = 0.91, 95% CI: 0.86, 0.98). No heterogeneity
was present in the classical meta-analysis (P = 0.78, I2 =
0%). There was no statistical multiplicative interaction
with the data source in the individual patient–level mega-
analysis (P = 0.46), nor could we observe statistically sig-
nificant additive interaction. Further stratification of the
study period to the “statin era” (January 2000 to August
2012) did not diminish the observed modestly decreased
risk of revision surgery (adjusted IRR = 0.91, 95% CI:
0.83, 0.99).
DISCUSSION
This study shows that there is probably no causal relation-
ship between statins and implant failure in patients with a re-
placed hip or knee. Both the case-control design (IRR = 0.87)
and the time-dependent cohort design (IRR = 0.90) revealed
a slight reduction in implant failure rates. However, the risk
did not decrease with a longer duration of statin use. The
time-fixed cohort analyses led to substantially lower risk es-
timates; this observation held for both time-fixed cohort de-
signs but was greater when immortal time was misclassified
(IRR = 0.36) than when it was excluded (IRR = 0.65). Differ-
ences in confounder-handling techniques or data sources did
not substantially alter the study findings.
Table 4. Risk of Orthopedic Implant Revision Surgery Among Statin Usersa in British and Danish Data Sets, Separately and in Aggregate, United
Kingdom and Denmark, 1987–2012
Adjustment and Data Set
Cohort Design
Case-Control DesignTime-Fixed
Time-Dependent
Method 1b Method 2c
IRR 95% CI IRR 95% CI IRR 95% CI IRR 95% CI
Unadjustedd
United Kingdom (CPRD) 0.51 0.47, 0.55 0.72 0.67, 0.78 0.90 0.84, 0.97 0.89 0.82, 0.95
Denmark (DNHS) 0.45 0.41, 0.50 0.80 0.73, 0.88 0.92 0.84, 1.01 0.92 0.83, 1.00
Meta-analysis 0.49 0.46, 0.52 0.75 0.71, 0.80 0.91 0.86, 0.96 0.90 0.85, 0.95
Mega-analysis 0.49 0.46, 0.52 0.75 0.71, 0.80 0.91 0.86, 0.96 0.90 0.85, 0.95
Age- and sex-adjusted
United Kingdom (CPRD) 0.50 0.46, 0.54 0.73 0.67, 0.78 0.93 0.86, 1.00 0.89 0.83, 0.96
Denmark (DNHS) 0.45 0.41, 0.49 0.80 0.73, 0.87 0.93 0.85, 1.02 0.92 0.84, 1.01
Meta-analysis 0.48 0.45, 0.51 0.75 0.71, 0.80 0.93 0.88, 0.99 0.90 0.85, 0.96
Mega-analysis 0.48 0.45, 0.51 0.75 0.71, 0.80 0.93 0.88, 0.99 0.91 0.86, 0.96
Fully adjustede
United Kingdom (CPRD) 0.36 0.33, 0.39 0.64 0.58, 0.71 0.92 0.84, 1.01 0.87 0.79, 0.95
Denmark (DNHS) 0.36 0.33, 0.40 0.65 0.59, 0.72 0.90 0.81, 0.99 0.85 0.76, 0.95
Meta-analysis 0.36 0.34, 0.38 0.65 0.63, 0.68 0.91 0.86, 0.98 0.86 0.80, 0.92
Mega-analysisf 0.36 0.34, 0.38 0.65 0.63, 0.68 0.90 0.85, 0.96 0.87 0.81, 0.93
Abbreviations: CI, confidence interval; CPRD, Clinical Practice Research Datalink; DNHS, Danish National Health System; IRR, incidence rate
ratio.
a Referent: no statin use (IRR = 1).
b Misclassification of immortal time.
c Exclusion of immortal time.
d Not adjusted for any of the potential confounders, including age and sex.
e Adjusted for confounders shown in Table 2.
f Adjusted for confounders shown in Table 2, excluding body mass index, smoking status, and alcohol use.
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In linewith our findings, Thillemann et al. (9) found an over-
all protective association of statins with implant failure, with
the absence of a clear dose-response relationship, in a Danish
case-control study. However, the magnitude of their observed
association (IRR = 0.34) was substantially greater than the
magnitudes of any of the incidence rate ratios we found in
our Danish case-control designs (lowest IRR = 0.85). In con-
trast to the first Danish study (9), we did not use dedicated
joint replacement registries to identify revision surgery. Theo-
retically, this might have led to underrecording of the outcome
in our study. The revision rate observed in our study, however,
was not lower than that in the first Danish study. Moreover, this
underrecording is likely to have been nondifferential, and it is
likely that the databases record revision surgery with near-
perfect specificity. Therefore, underrecording should not
have had a major influence on the incidence rate ratios.
There is conflicting evidence on the beneficial effects of
statins on bone metabolism. In vitro and in vivo, statins inhibit
osteoclast-mediated bone resorption, by reducing mevalonic
acid formation (12). However, randomized controlled trials
could not confirm this potential benefit on fracture risk (14).
While some observational studies suggested a protective effect
for statins in preventing fracture (7), others could not find such
an association (13).
The difference between the time-fixed and time-dependent
cohort designs emphasizes the importance of immortal time
bias. In time-fixed cohorts, the immortal time can be either
misclassified or excluded (Figure 1). Both may lead to sub-
stantial bias, as was shown in our study. Misclassification of
immortal time results in lengthened person-time among statin
users and shortened person-time among nonusers (both result-
ing in a downward bias). Exclusion of immortal time shortens
person-time only among nonusers, which results in a down-
ward bias as well, albeit less pronounced than when immortal
time is misclassified. Time-dependent cohort or nested case-
control designs are appropriate methods for preventing im-
mortal time bias (22). Because case-control designs do not
take person-time into account, there is no misclassification
or selection of immortal time bias by definition. Our example
showed that these 2 designs were comparable in terms of the
overall association as well as in the duration-of-use analysis.
The various methods for dealing with confounding did not
produce differences in the rate ratios. This is in line with a sim-
ulation study comparing various propensity score methods with
conventional regression adjustment (23). In this simulation
study, propensity adjustment, propensity matching, and conven-
tional regression adjustment were comparable in terms of bias
reduction and precision. However, propensity scores perform
better when a large number of prognostic factors are included
in the regression model, the treatment effect becomes larger,
and the incidence of the outcome increases (24). It seems that
these differences are based on artifacts in the conventional re-
gression model under these circumstances rather than on a better
handling of confounding by indication or residual confounding.
Interestingly, themagnitude of immortal time bias became larger
with more intense modeling. This could be explained by un-
healthy bias (adjusting for unhealthy status among statin users
may amplify the immortal time bias) or modeling artifacts (24).
The use of different data sources was not a discriminating
factor in this example of statins and implant revision. Although
the British and Danish electronic health records differ in some
important aspects, the results in the incidence rate ratio analyses
were comparable. Absolute revision rates were substantially
higher in the Danish population than in British individuals.
This was probably the result of underrecording using general
practice electronic health records.
Strengths of this study included a large sample size, longitu-
dinal follow-up, use of data sources from multiple countries,
the ability to compare different study designs, and the availabil-
ity of routinely collected data on exposure, outcome, and poten-
tial confounders. The routine data collection allowed us to
analyze very fine timing patterns with the precision of a single
day. A major limitation of our study is that we used a proxy
measure for implant failure—revision surgery. Revision sur-
gery after implant failuremay be conditional on surgical fitness,
and this may have distorted our study findings. Furthermore,
statin use—in particular, adherence to statin use—may be asso-
ciated with healthy user bias. There is a chance that revision
surgery was underrecorded, but this is likely to have been non-
differential. When using the case-control design, we were not
able to ensure that recording of data on covariates preceded ex-
posure. It may be postulated that, ideally, data recording should
precede exposure, even in a case-control design. However, our
primary objective was to mimic widely used methodologies.
Because in most case-control studies, covariates are assessed
prior to the index date (here, the date of revision surgery) rather
than prior to ascertainment of exposure status, we aimed to
mimic this methodology as much as possible. Moreover, it is
difficult to ensure that data recording precedes exposure, in par-
ticular when the case or control patient is “unexposed” (in case-
control designs, it is then unclear what the date of exposure as-
certainment should be).
In conclusion, statins probably do not prevent implant fail-
ure in individuals with a TJR surgery. Despite a small inverse
association, the duration-of-use analysis did not support
a causal relationship. The time-fixed cohort designs resulted
in a substantially biased risk estimate, regardless of the type
of time-fixed design. Confounder-handling techniques (in-
cluding propensity score analyses) and type of electronic
health record seemed to play only a minor role in differences
in study findings. When the association between statin use
and revisions after TJR is evaluated, conventional study de-
signs such as case-control designs or cohort designs that take
into account time-varying aspects of exposure are better than
time-fixed cohort study designs. From a clinical perspective,
this study does not support the use of statins to prevent joint
implant failure in patients who underwent primary total hip or
knee replacement surgery.
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